Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 62
Posts 3,697
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
U.s. Consumer Prices Fall 0.2% In August
The consumer-price index fell a seasonally adjusted 0.2% in August from a month earlier, the Labor Department said. The index was unchanged after excluding volatile food and energy categories.
More Top Equities Stories Of The Day
Adobe, Rackspace Losses Take Tech Spotlight
China Foreign Direct Investment at Four-Year Low -- Update
ASX Offers to Buy 49% Stake in Yieldbroker
Americans Support Striking Islamic Militants, Poll Shows
U.S. Steel Canada to Seek Creditor Protection
U.S. Hot Stocks: Hot Stocks to Watch
U.S. Hog Futures Pressured by Profit-Taking; Cattle Advance
U.S. stocks were mixed, but technology stocks suffered sharp losses in cautious trading
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 182035 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist